Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
pediatric drug development
Biotech
In another reversal, FDA to reconsider Regenxbio gene therapy
The agency has reversed its previous demand that Regenxbio use an untreated control arm for the one-time Hunter syndrome candidate.
Angus Liu
Jun 22, 2026 10:26am
Minovia Therapeutics nabs Jacobs as new CMO
Mar 12, 2021 9:45am
Day One bags $60M to change cancer care—starting with children
May 21, 2020 8:00am
Ipsen scraps pivotal trial as partial clinical hold drags on
Mar 26, 2020 8:45am
Lawmakers propose 7% increase in NIH funding
Dec 17, 2019 8:20am
Amicus shares early look at Batten disease gene therapy
Aug 1, 2019 8:17am
